Avidity Biosciences Completes $72.00/Share Acquisition by Novartis AG; Spin-Off of Atrium Therapeutics Finalized, Delisting Imminent

summarizeSummary

Avidity Biosciences, Inc. announced the completion of its acquisition by Novartis AG for $72.00 per share in cash, alongside the spin-off of Atrium Therapeutics, Inc. to its stockholders, marking the end of its independent public trading.

check_boxKey Events

• Merger Completed

  Avidity Biosciences was acquired by Novartis AG for $72.00 per share in cash, becoming an indirect wholly-owned subsidiary. This follows the stockholder approval reported yesterday, February 26, 2026.

• Atrium Therapeutics Spin-Off Finalized

  The spin-off of Atrium Therapeutics, Inc. was completed on February 26, 2026, distributing one share of SpinCo common stock for every ten shares of Avidity common stock held as of February 12, 2026. Atrium Therapeutics now operates as a separate, independent, publicly held company.

• Equity Awards Converted to Cash

  Company Stock Options and RSUs (excluding New Hire RSUs) became fully vested and converted into cash payments based on the $72.00 merger consideration. New Hire RSUs converted into cash awards subject to service-based vesting.

• Delisting from Nasdaq Imminent

  Avidity Biosciences' common stock will be suspended from trading on Nasdaq on March 2, 2026, with the company intending to terminate its SEC registration and reporting obligations.

auto_awesomeAnalysis

This filing confirms the definitive completion of the previously announced acquisition of Avidity Biosciences by Novartis AG, with shareholders receiving $72.00 in cash for each common share. This transaction fundamentally alters the company's structure, as it now operates as an indirect wholly-owned subsidiary of Novartis. Concurrently, the spin-off of Atrium Therapeutics, Inc., which holds Avidity's early-stage precision cardiology programs, has been finalized, creating a new independent public company for Avidity's former stockholders. The completion of the merger also triggers the termination of all existing equity plans, the ESPP, and the At-The-Market (ATM) sales agreement, removing any potential future dilution from those programs. The company's common stock will be delisted from Nasdaq on March 2, 2026, and its SEC reporting obligations will cease, signifying the end of its life as a publicly traded entity.